Catalpa seed oil rich in 9\textit{t},11\textit{t},13\textit{c}-conjugated linolenic acid suppresses the development of colonic aberrant crypt foci induced by azoxymethane in rats

RIKAKO SUZUKI\textsuperscript{1}, YUMIKO YASUI\textsuperscript{2}, HIROYUKI KOHNO\textsuperscript{1}, SHINGO MIYAMOTO\textsuperscript{1,3}, MASASHI HOSOKAWA\textsuperscript{2}, KAZUO MIYASHITA\textsuperscript{2} and TAKUJI TANAKA\textsuperscript{1}

\textsuperscript{1}Department of Oncologic Pathology, Kanazawa Medical University, 1-1 Daigaku, Uchinada, Ishikawa 920-0293; \textsuperscript{2}Graduate School of Fisheries Sciences, Hokkaido University, 3-1-1 Minato, Hakodate, Hokkaido 041-8611; \textsuperscript{3}Division of Food Science and Biotechnology, Graduate School of Agriculture, Kyoto University, Kyoto 606-8502, Japan

Received May 3, 2006; Accepted June 2, 2006

Abstract. Catalpa (\textit{Catalpa ovata}) seed oil (CPO) is a unique oil that contains a high amount of 9\textit{trans},11\textit{trans},13\textit{cis}-conjugated linolenic acid. In the present study, we investigated whether dietary administration with CPO affects the development of azoxymethane (AOM)-induced colonic aberrant crypt foci (ACF) in male F344 rats to elucidate its possible cancer chemopreventive efficiency. Also, the effect of CPO on the fatty acid composition of liver tissue and colonic mucosa, the serum levels of total cholesterol and triglyceride, and the mRNA expression of cyclooxygenase (COX)-2 in the colonic mucosa were measured. In addition, the cell proliferation activity and apoptotic index in the colonic mucosa were estimated immunohistochemically. Animals were given two weekly subcutaneous injections of AOM (20 mg/kg body weight). They also received the experimental diet containing 0.01%, 0.1% or 1% CPO for 4 weeks, starting one week before the first dosing of AOM. AOM exposure produced a substantial number of ACF (99±28) at the end of the study (week 4). Dietary administration of CPO reduced the number of ACF (AOM + 0.01% CPO, 32±11, P<0.001; AOM + 0.1% CPO, 35±18, P<0.001; AOM + 1% CPO, 18±10, P<0.001). 9\textit{t},11\textit{t}-conjugated linoleic acid was detected in the liver tissue and colonic mucosa of rats fed the CPO-containing diet. Additionally, dietary administration with CPO decreased the serum triglyceride level and the expression of COX-2 mRNA in the colonic mucosa. The indices of cell proliferation and apoptosis in the colonic mucosa of rats treated with AOM and 1% CPO have significant differences when compared with the AOM alone group. These findings suggest the possible chemopreventive activity of CPO in the early phase of colon carcinogenesis.

Introduction

Colon cancer is one of the leading causes of cancer deaths in Asia and Western countries (1,2). Therefore, it is a major public health problem around the world. Dietary factors, including a high fat content, influence colon cancer development (1,2). Intake of n-3 polyunsaturated fatty acid (PUFA) is reported to prevent colorectal carcinogenesis (3,4), while excessive consumption of n-6 PUFAs can promote colon cancer development (5). The type of dietary fat consumption is thus important for development of colonic malignancy.

Recently, conjugated fatty acids (CFAs) have received a great deal of attention because of their numerous beneficial biological effects including cancer preventive property (6-8). CFAs refer to a group of positional and geometric isomers of PUFAs containing conjugated double bonds. One of the CFAs, conjugated linoleic acid (CLA), is well-known for its biological effects. Regarding the inhibitory effect of cancer, CLA can inhibit chemically-induced skin, mammary, forestomach, and colon tumorigenesis in rodents (9-12). Although CLA is present in certain foods such as milk fat and meats derived from ruminant animals, the content is less than 1% (13).

On the other hand, some plant seed oils contain a large amount of conjugated linolenic acid (CLN). α-Eleostearic acid (9c,11t,13r-CLN) in tung and bitter melon seed oil (BMO) are present at 67.7% and 56.2%, respectively (14). The seed oils of pomegranate, catalpa, and pot marigold contain 83.0% punicic acid (9c,11t,13c-CLN), 42.3% catalpic acid (9c,11t,13c-CLN), and 62.2% calendic acid (8t,10t,12c-CLN), respectively (14). As for the biological activity of CLN, dietary CLN produced by alkaline isomerization of linolenic acid (LN) reduces fat content in the body (15). Purified punicic acid has a hypolipidemic effect (16). Additionally the antihyperglycemic property of pomegranate seed oil (PGO) has been reported (17). Also we and other researchers have shown the cytotoxic effect of PGO and tung oil on a variety of human cancer cell lines, including colon cancer cells (18,19).
Table I. Fatty acid composition of CPO.

<table>
<thead>
<tr>
<th>Fatty acid (wt%)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>16:0</td>
<td>2.8</td>
</tr>
<tr>
<td>18:0</td>
<td>2.2</td>
</tr>
<tr>
<td>18:1 n-9</td>
<td>7.6</td>
</tr>
<tr>
<td>18:2 n-6</td>
<td>42.5</td>
</tr>
<tr>
<td>18:3 n-3</td>
<td>0.6</td>
</tr>
<tr>
<td>9c:11r,13c-CLN</td>
<td>0.1</td>
</tr>
<tr>
<td>9c:11r,13r-CLN</td>
<td>0.1</td>
</tr>
<tr>
<td>9r,11r,13c-CLN</td>
<td>40.2</td>
</tr>
<tr>
<td>Others</td>
<td>3.9</td>
</tr>
</tbody>
</table>

Regarding the in vivo studies, CLN derived from perilla oil suppresses chemically-induced mammary adenocarcinomas in rats (10). We also found that dietary BMO inhibits the development of aberrant crypt foci (ACF) (20) that are precursor lesions of colon cancer (21). In addition, our recent studies demonstrated that BMO and PGO suppressed azoxy-methane (AOM)-induced colon carcinogenesis in rats (12,22). Regarding catalpa seed oil (CPO), we reported the cytotoxic effect of CPO on SV40-transformed Balb 3T3 A31 and human monocytic leukemia cell lines (18), but there are no in vivo studies on the effect of CPO on carcinogenesis.

In the present study, we investigated the influence of CPO in the development of AOM-induced ACF to elucidate the modifying effect of CPO on rat colon carcinogenesis. Additionally, we analyzed the lipid composition of liver tissue and colonic mucosa and measured the serum concentrations of total cholesterol and triglyceride to understand the possible mechanisms by which CPO could modify the occurrence of the lesions. Since overexpression of cyclooxygenase-2 (COX-2) is involved in colon carcinogenesis and certain cyclooxygenase inhibitors are likely to be useful as colon cancer chemopreventive agents (23-26), the effects of CPO on the expression of COX-2 in the non-lesional colonic mucosa were investigated. Also, biomarkers such as proliferating cell nuclear antigen (PCNA)-labeling index and apoptotic index were measured immunohistochemically in colonic mucosa, since BMO exerted an inhibitory effect on ACF via reduction of the PCNA index and induction of apoptosis in our previous study (20).

Materials and methods

Animals, chemicals, and diets. Male F344 rats (Charles River Japan, Inc., Tokyo, Japan) aged 4 weeks were used. The animals were maintained at Kanazawa Medical University Animal Facility according to the Institutional Animal Care Guidelines. They were housed in plastic cages (4 rats/cage) with free access to tap water and diet, under controlled conditions of humidity (50±10%), lighting (12-h light/dark cycle), and temperature (23±2°C). They were quarantined for 7 days and randomized by body weight into experimental and control groups. AOM for ACF induction was purchased from Sigma Chemical Co. (St. Louis, MO, USA). AIN-76A diet (LSG Corporation, Tokyo, Japan) was used as basal diet throughout the study. Seeds of catalpa (Catalpa ovata) were kindly donated from Tohoku Seed Co. (Tochigi, Japan). Seed oil was extracted by n-hexane after crushing with an electric mill. Determination of fatty acid profile of the total lipids in CPO (Table I) was carried out according to the methods described previously (20).

Experimental procedure. A total of 40 male F344 rats were divided into five experimental groups and a control group (Fig. 1). Animals in groups 1 through 4 were initiated with AOM by two weekly subcutaneous injections (20 mg/kg body weight). Rats in groups 1 and 6 were fed the basal diet containing 5% corn oil. The diets for groups 2 and 3 were replaced by 0.01% and 0.1% CPO in the 5% corn oil, respectively. Groups 4 and 5 were given the diet containing 1% CPO and 4% corn oil. These diets were fed to rats for 4 weeks, starting one week before the first dosing of AOM. All rats were freely available for diet and tap water. All experimental diets containing CPO were prepared weekly in our laboratory and stored at -20°C under a nitrogen atmosphere in airtight containers for no longer than a week. Rats were provided with the diet every day and the peroxide value of the lipids in the fresh diets was less than 3.0 meq/kg lipid.

The rats were sacrificed under ether anesthesia at week 4 and underwent careful necropsy, with emphasis on the colon, liver, kidney, lung, and heart. The colons of five rats each from groups 1 through 4 and those of two rats each from groups 5 and 6 were fixed in 10% buffered formalin for assessing the occurrence of colonic ACF. The colons of the remaining rats were used for determining the expression of COX-2 protein and lipid analysis in colonic mucosa. The liver was weighed and the caudate lobe was removed and fixed in 10% buffered formalin for histological examination. Remaining lobes of the livers of all rats were used for analyses of fatty acid composition. All other tissues were fixed in 10% buffered formalin and submitted to histological examination.

Determination of ACF. The presence of ACF was determined according to the standard procedures that are routinely used in our laboratory (27). At necropsy, the colons were flushed with saline, excised, cut open longitudinally along the main axis, and then washed with saline. They were cut, placed on the filter paper, with their mucosal surface up, and then fixed in 10% buffered formalin for at least 24 h. Fixed colons were stained with methylene blue (0.5% in distilled water) for
Table II. Body, liver, and relative liver weights in each group.

<table>
<thead>
<tr>
<th>Group no.</th>
<th>Treatment (no. of rats examined)</th>
<th>Body weight (g)</th>
<th>Liver weight (g)</th>
<th>Relative liver weight (g/100 g body weight)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>AOM alone (8)</td>
<td>209±11</td>
<td>8.4±0.7</td>
<td>4.03±0.33</td>
</tr>
<tr>
<td>2</td>
<td>AOM + 0.01% CPO (8)</td>
<td>198±5</td>
<td>7.2±0.7</td>
<td>3.61±0.38</td>
</tr>
<tr>
<td>3</td>
<td>AOM + 0.1% CPO (8)</td>
<td>197±13</td>
<td>6.9±0.9b</td>
<td>3.51±0.24</td>
</tr>
<tr>
<td>4</td>
<td>AOM + 1% CPO (8)</td>
<td>203±10</td>
<td>8.4±1.3</td>
<td>4.12±0.46</td>
</tr>
<tr>
<td>5</td>
<td>1% CPO (4)</td>
<td>204±8</td>
<td>7.8±0.5</td>
<td>3.80±0.30</td>
</tr>
<tr>
<td>6</td>
<td>No treatment (4)</td>
<td>199±11</td>
<td>8.5±1.3</td>
<td>4.25±0.46</td>
</tr>
</tbody>
</table>

*aMean ± SD. bSignificantly different from group 1 by Bonferroni Multiple Comparisons test (P<0.05).

Lipid extraction and analysis. Tissue lipids were extracted by the Folch method using chloroform/methanol (2:1, v/v) (28). Fatty acid methyl esters were analyzed by GC-FID (SHIMADZU GC-14B gas chromatograph, Shimadzu Seikusako Co., Ltd., Kyoto, Japan) equipped with an Omegawax 320 capillary column (30 m x 0.32 mm I.D.). Peaks were identified by comparison with fatty acid standards (Nu-chek-Prep, MN, USA), and area and its percentage for each resolved peak were analyzed using Shimadzu Chromatopac C-R3A integrator (Shimadzu Seikusako Co., Ltd.).

Measurements for the level of serum cholesterol and triglyceride. Serum cholesterol and triglyceride levels in rats were measured by enzymatic method using an Ekdia-L-Eiken kit according to the manufacturer's protocol (Eiken Chemical Co., Ltd., Tokyo, Japan).

Determination of COX-2 mRNA level in colonic mucosa by real-time PCR. For quantitative real-time PCR, total RNA was extracted from colonic mucosa using a Qiagen RNeasy mini kit (Qiagen, CA, USA) after homogenization using a Qiashredder column (Qiagen), and stored at -80°C. Total RNA was reverse transcribed by the High Capacity cDNA Archive kit (Applied Biosystems, CA, USA). cDNA was subjected to quantitative real-time PCR using TaqMan gene expression assay (Applied Biosystems) and TaqMan Universal PCR Master Mix (Applied Biosystems). An ABI PRISM 7000 system (Applied Biosystems) was used for the reaction and detection of the expression of COX-2 and β-actin mRNA. PCR amplification was performed in a total volume of 25 μl containing 11.25 μl cDNA template, 12.5 μl of 2X TaqMan Universal PCR Master Mix, and 1.25 μl of 20X TaqMan gene expression assay. For each reaction the AmpErase UNG and AmpliTaq Gold Enzyme were activated at 50°C for 2 min and 95°C for 10 min, respectively. Amplification was then performed by 40 cycles of 95°C for 15 sec and 60°C for 1 min.

Immunohistochemistry. Immunohistochemistry for the PCNA and apoptotic nuclei was performed on 4-μm-thick paraffin-embedded sections from colons of rats in each group by the labeled streptavidin biotin method using a LSAB KIT (Dako Japan, Kyoto, Japan) with microwave accentuation. The paraffin-embedded sections were heated for 30 min at 65°C, deparaffinized in xylene, and rehydrated through graded ethanol at room temperature. A 0.05-M Tris HCl buffer (pH 7.6) was used to prepare solutions and for washes between various steps. Incubations were performed in a humidified chamber. For the determination of PCNA-incorporated nuclei, PCNA-immunohistochemistry was performed according to the method described by Watanabe et al (31). Apoptotic index was also evaluated by immunohistochemistry for single-stranded DNA (ssDNA) (31). Sections were treated for 40 min at room temperature with 2% BSA and incubated overnight at 4°C with primary antibodies. Primary antibodies included anti-PCNA mouse monoclonal antibody (diluted 1:50; PC10, Dako Japan) and anti-ssDNA rabbit polyclonal antibody (diluted 1:300, Dako Japan). Horseradish peroxidase activity was visualized by treatment with H2O2 and 3,3'-diaminobenzidine for 5 min. At the last step, the sections were weakly counterstained with Mayer's hematoxylin (Merck Ltd., Tokyo, Japan). For each case, negative controls were performed on serial sections. On the control sections, incubation with the primary antibodies was omitted. Intensity and localization of immunoreactivities against two primary antibodies used were examined on all sections using a microscope (Olympus BX41, Olympus Optical Co., Ltd., Tokyo, Japan). The PCNA and apoptotic indices were determined by counting the number of positive cells among at least 200 cells in the lesion, and were indicated as percentages.

Statistical evaluation. Where applicable, data were analyzed using one-way ANOVA with Bonferroni correction test with P<0.05 as the criterion of significance.

Results

General observation. Body, liver, and relative liver weights (g/100 g body weight) in all groups are shown in Table II. All animals remained healthy throughout the experimental period. Food consumption (g/day/rat) did not differ significantly among the groups (data not shown). At the end of the study,
there were no significant differences in the mean body weight among the groups. Although the liver weight of group 3 was statistically lower than that of group 1 (P<0.05), the mean relative liver weights did not show significant differences among the groups.

ACF analysis. The data on colonic ACF (Fig. 2) formation are summarized in Table III. All rats belonging to groups 1 through 4, which were given AOM, developed ACF. When compared to the mean number of ACF/colon in group 1 (AOM alone, 99±28), the dietary administration of 0.01%
and 1% (group 4, 18±10, P<0.001) CPO significantly reduced the number of ACF: 68% inhibition in group 2, 65% inhibition in group 3, and 82% inhibition in group 4. Furthermore, significant decreases were found in the number of aberrant crypts (ACs) per colon (P<0.001) and the number of ACs/focus (P<0.001) in groups 2 through 4 when compared to those in group 1. Also the percentages of ACF consisting of more than 4 ACs in groups 2 (1.25±2.80, P<0.001), 3 (1.30±1.78, P<0.001), and 4 (1.62±2.25, P<0.001) were significantly smaller than that of group 1 (32.13±4.28). In groups 5 and 6, there was no microscopically observable change, including ACF, in the colonic mucosa.

Lipid analysis. The fatty acid profiles of the lipids from the liver tissue and colonic mucosa are shown in Tables IV and V, respectively. CPO diets contained ~40% of catalpic acid (9t,11t,13c-CLN), however it was not detected in these tissues of rats fed CPO-containing diets at three different doses. On the other hand, the contents of CLA (9t,11t-18:2) in the same tissues were elevated in a dose-dependent manner. Although the CPO diets contained >40% of linoleic acid (LA), the amount of LA in the groups administered the CPO-containing diet was insignificant compared with that in the groups fed the diet without CPO.

Serum concentration of total cholesterol and triglycerides. Serum concentrations of total cholesterol and triglycerides are summarized in Fig. 3. The total cholesterol level in the AOM + 0.01% CPO group (67.4±6.0 mg/dl) was lower than that in the AOM alone group (77.4±6.2 mg/dl) without statistical significance. Serum triglyceride levels of rats that were fed the AOM + CPO diet (the AOM + 0.01% CPO group: 77.2±18.7 mg/dl; the AOM + 0.1% CPO group: 69.0±12.7 mg/dl; and the AOM + 1% CPO group: 44.6±7.6 mg/dl) were reduced dose dependently, when compared to the AOM alone group (94.6±4.0 mg/dl). A significant difference (P<0.05) was detected between the AOM + 1% CPO and AOM alone group.

Expression of COX-2 mRNA levels in colonic mucosa. As illustrated in Fig. 4, expression of COX-2 mRNA level was (group 2, 32±11, P<0.001), 0.1% (group 3, 35±18, P<0.001), and 1% (group 4, 18±10, P<0.001) CPO significantly reduced the number of ACF: 68% inhibition in group 2, 65% inhibition in group 3, and 82% inhibition in group 4. Furthermore, significant decreases were found in the number of aberrant crypts (ACs) per colon (P<0.001) and the number of ACs/focus (P<0.001) in groups 2 through 4 when compared to those in group 1. Also the percentages of ACF consisting of more than 4 ACs in groups 2 (1.25±2.80, P<0.001), 3 (1.30±1.78, P<0.001), and 4 (1.62±2.25, P<0.001) were significantly smaller than that of group 1 (32.13±4.28). In groups 5 and 6, there was no microscopically observable change, including ACF, in the colonic mucosa.

Lipid analysis. The fatty acid profiles of the lipids from the liver tissue and colonic mucosa are shown in Tables IV and V, respectively. CPO diets contained ~40% of catalpic acid (9t,11t,13c-CLN), however it was not detected in these tissues of rats fed CPO-containing diets at three different doses. On the other hand, the contents of CLA (9t,11t-18:2) in the same tissues were elevated in a dose-dependent manner. Although the CPO diets contained >40% of linoleic acid (LA), the amount of LA in the groups administered the CPO-containing diet was insignificant compared with that in the groups fed the diet without CPO.

Serum concentration of total cholesterol and triglycerides. Serum concentrations of total cholesterol and triglycerides are summarized in Fig. 3. The total cholesterol level in the AOM + 0.01% CPO group (67.4±6.0 mg/dl) was lower than that in the AOM alone group (77.4±6.2 mg/dl) without statistical significance. Serum triglyceride levels of rats that were fed the AOM + CPO diet (the AOM + 0.01% CPO group: 77.2±18.7 mg/dl; the AOM + 0.1% CPO group: 69.0±12.7 mg/dl; and the AOM + 1% CPO group: 44.6±7.6 mg/dl) were reduced dose dependently, when compared to the AOM alone group (94.6±4.0 mg/dl). A significant difference (P<0.05) was detected between the AOM + 1% CPO and AOM alone group.

Expression of COX-2 mRNA levels in colonic mucosa. As illustrated in Fig. 4, expression of COX-2 mRNA level was

Table IV. Effect of CPO diets on fatty acid composition of liver lipids.

<table>
<thead>
<tr>
<th>Group no. (no. of rats examined)</th>
<th>Treatment</th>
<th>Fatty acid (wt%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 AOM alone (8)</td>
<td>23.6±0.8</td>
<td>5.7±1.1</td>
</tr>
<tr>
<td>2 AOM + 0.01% CPO (8)</td>
<td>24.1±1.7</td>
<td>5.2±1.3</td>
</tr>
<tr>
<td>3 AOM + 0.1% CPO (8)</td>
<td>23.7±1.6</td>
<td>5.4±1.3</td>
</tr>
<tr>
<td>4 AOM + 1% CPO (8)</td>
<td>22.9±1.0</td>
<td>4.5±0.2</td>
</tr>
<tr>
<td>5 1% CPO (4)</td>
<td>25.3±1.3</td>
<td>5.3±0.7</td>
</tr>
<tr>
<td>6 No treatment (4)</td>
<td>26.9±1.2</td>
<td>6.7±0.7</td>
</tr>
</tbody>
</table>

Mean ± SD. N.D., not detected.

Table V. Effect of CPO diets on fatty acid composition of colonic mucosa.

<table>
<thead>
<tr>
<th>Group no. (no. of rats examined)</th>
<th>Treatment</th>
<th>Fatty acid (wt%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 AOM alone (5)</td>
<td>28.3±1.2</td>
<td>8.9±1.2</td>
</tr>
<tr>
<td>2 AOM + 0.01% CPO (5)</td>
<td>29.2±0.9</td>
<td>9.6±0.9</td>
</tr>
<tr>
<td>3 AOM + 0.1% CPO (5)</td>
<td>28.9±1.1</td>
<td>9.9±1.1</td>
</tr>
<tr>
<td>4 AOM + 1% CPO (5)</td>
<td>29.6±0.3</td>
<td>9.4±0.2</td>
</tr>
<tr>
<td>5 1% CPO (2)</td>
<td>30.2±0.6</td>
<td>10.5±0.6</td>
</tr>
<tr>
<td>6 No treatment (2)</td>
<td>31.1±0.3</td>
<td>10.1±0.3</td>
</tr>
</tbody>
</table>
Comparisons test (bP<0.05 and cP<0.01).

4 AOM + 1% CPO (5) 15.2±3.2b 8.2±1.3c
3 AOM + 0.1% CPO (5) 17.4±2.9 6.8±1.5
2 AOM + 0.01% CPO (5) 18.8±4.1 5.4±2.3

administration with CPO that contains a large amount of The results described here clearly indicate that dietary effects on food intake or growth rate and no histological alterations in any organs. These findings may suggest that dietary CPO suppresses the early phase of chemically-induced colon carcinogenesis. Previously we reported that dietary administration with 9c,11t,13t-CLN caused a significant reduction in the frequency of ACF (19% reduction by 0.01% 9c,11t,13t-CLN, 36% reduction by 0.1% 9c,11t,13t-CLN, and 63.0% reduction by 1% 9c,11t,13t-CLN) (20). In the present study, the inhibition rates of the total number of ACF at 0.01, 0.1, and 1% CPO were 68, 65, and 82%, respectively. This may suggest that the distinction of geometric isomers of CLN might have an explanation for such differences of inhibition rate. Despite CPO containing a significant amount of LA that influences colorectal cancer (5), colonic ACF was suppressed by CPO. Our findings may suggest that 9t,11t,13-18:3 in CPO is a good natural chemopreventive agent against colon carcinogenesis.

COX enzymes play a central role in the conversion of arachidonic acid (AA) to prostaglandins. One of the COX-2 reaction products, PGE2, is known to lead to the induction of cell proliferation and the inhibition of apoptosis which favor tumor development (23,26). Suppression of the enzyme COX is suggested to be the potential mechanism for inhibition of carcinogenesis. In colon carcinogenesis, overexpression of COX-2 was observed in ACF, adenomas, and adenocarcinomas (32), suggesting that the over-expression of COX-2 contributes to the growth of precursor lesions and tumors and their progression. In fact, treatment with the selective COX-2 inhibitor celecoxib gave us promising results in the prevention of colorectal cancer (26). Also Rao et al (24) demonstrated that celecoxib significantly reduced AOM-induced rat colon ACF. In the current study, dietary administration with CPO reduced COX-2 mRNA expression in the colonic mucosa, and this may account for lowering the number of colonic ACF. Since CLA causes down-regulation of COX-2 activity (33), accumulated CLA in the colonic mucosa might also contribute to reducing the expression of COX-2 mRNA.

In the current study, dietary administration with CPO decreased cell proliferation activity and increased apoptosis index in the AOM-induced rat colonic mucosa. Also, down-expression of anti-apoptosis protein, bel-xL, was found in the colonic mucosa of rats treated with AOM and CPO (data not shown). Previously, we reported that BMO has the ability to decrease the PCNA-labeling index and enhance the apoptosis-index (20). Thus, the inhibitory effect of CPO on ACF might partly be due to modulation of cell proliferation and apoptosis. Since inhibition of COX-2 expression results in resistance to cell proliferation and increased apoptosis (23,26), the reduction of COX-2 mRNA expression in the present study might contribute to the modulation effect of CPO on cell proliferation and apoptosis.

Figure 4. Effect of CPO diet on COX-2 mRNA expression in rat colon mucosa.

Table VI. PCNA and apoptosis indices in rat colonic mucosa.

<table>
<thead>
<tr>
<th>Group no.</th>
<th>Treatment (no. of rats examined)</th>
<th>PCNA-labeling index (%)</th>
<th>Apoptotic index (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>AOM alone (5)</td>
<td>24.6±5.6a</td>
<td>3.8±0.8</td>
</tr>
<tr>
<td>2</td>
<td>AOM + 0.01% CPO (5)</td>
<td>18.8±4.1</td>
<td>5.4±2.3</td>
</tr>
<tr>
<td>3</td>
<td>AOM + 0.1% CPO (5)</td>
<td>17.4±2.9</td>
<td>6.8±1.5</td>
</tr>
<tr>
<td>4</td>
<td>AOM + 1% CPO (5)</td>
<td>15.2±3.2b</td>
<td>8.2±1.3c</td>
</tr>
</tbody>
</table>

*aMean ± SD. bSignificantly different from group 1 by Bonferroni Multiple Comparisons test*.

Table VI. PCNA and apoptosis indices in rat colonic mucosa.

**Discussion**

The results described here clearly indicate that dietary administration with CPO that contains a large amount of catalpic acid (9t,11t,13t-CLN) significantly reduced AOM-induced rat ACF formation at any dose level (0.01%, 0.1%, or 1%) as compared with the rats injected with AOM alone. Also, animals fed the diets containing CPO showed no adverse effects on food intake or growth rate and no histological alterations in any organs. These findings may suggest that dietary CPO suppresses the early phase of chemically-induced colon carcinogenesis. We found a dose-dependent accumulation of 99,11t,18:2 in the colonic mucosa and liver tissue of rats that were fed CPO. Also the contents of 9t,11t,18:2 in the colonic mucosa and liver tissue of rats given PGO that contained over 70% of 99,11t,13t-18:3 were elevated in a dose-dependent manner (12). Others reported that CLA generated in rats after 9t,11t,13t-18:3 administration was confirmed to be 9t,11t,18:2 (34). We speculated that 9t,11t,13t-18:3 rich in CPO was saturated at the Δ13 position and converted to 9t,11t,18:2 in the current study. We and others reported that CLA inhibits the occurrence of chemically-induced colonic ACF (35) and tumor (12) in rats. Also 9t,11t,18:2 can suppress the growth of human cancer cells (36). Therefore, 9t,11t,18:2
converted from 9,11,13-18:3 might contribute to prevention of the development of colonic preneoplasms in the present study. CPO contains 40% LA besides catalpic acid. After intake of LA, it can be oxidized, stored in triacylglycerides, incorporated into membranous phospholipids, or elongated and desaturated to more unsaturated fatty acids such as γ-linolenic acid (LN), dihomo-γ-LN, and AA. Excess of n-6 PUFA consumption is one of the causes of colorectal cancer development (5). Administration of an LA-enriched diet also enhanced chemically-induced rat ACF occurrence and multiplicity (37). In the current study, the amounts of LA and AA of colonic mucosa and liver lipids in groups 2 through 4 did not significantly differ from those in group 1. These modifying effects of CPO on fatty acid profile in colonic mucosa or liver lipid might partly influence its inhibitory ability in ACF formation.

Serum levels of triglycerides and cholesterol have been shown to be positively associated with colon carcinogenesis (38,39). Niho et al. found that serum levels of triglycerides in Min mice are dramatically increased compared to the wild-type and the increase contributes to the growth of small intestinal polyps (40). They also demonstrated that a peroxisome proliferator-activated receptors (PPARγ) ligand suppresses both serum triglyceride level and intestinal polyp formation in Min mice (40). A synthetic ligand for PPARγ can inhibit AOM-induced rat colonic ACF (41) and colitis-related mouse colon cancer development (42). These findings suggest that activation of PPARγ is beneficial for colon cancer prevention. Since BMO containing ω6,18:2ω6,18:3 can up-regulate PPARγ (44), it may be possible that accumulated CLA or linoleate metabolites activated PPARγ in this study. Although we did not determine PPARγ expression in the colon, possible modulatory effects of CPO may partly contribute to its inhibitory effect on ACF occurrence.

In conclusion, the findings described here demonstrate for the first time that dietary administration of CPO rich in catalpic acid (9,11,13-18:3-CLN) significantly inhibited the development of AOM-induced ACF in rats. Although the exact mechanisms by which CPO inhibits colonic early preneoplastic lesions remain to be elucidated, it would be worthwhile to test the cancer chemoprevention ability of CPO using a long-term colon carcinogenesis model.

Acknowledgements

We express our thanks to the staff of the Research Animal Facility, Kanazawa Medical University. This study was supported by the Grant-in-Aid for Cancer Research from the Ministry of Health, Labour and Welfare of Japan; the Grant-in-Aid for the 3rd Term for a Comprehensive 10-year Strategy for Cancer Control from the Ministry of Health, Labour and Welfare of Japan; the Grants-in-Aid for Scientific Research (nos. 15-205200/20029 and 18592076) from the Ministry of Education, Culture, Sports, Science and Technology of Japan; and grants (H2005-6 and C2005-3) from Kanazawa Medical University.

References